Nivolumab versus everolimus in advanced renal cell carcinoma: Japanese subgroup analysis from the CheckMate 025 study.

about

Immunotherapy in the Asiatic population: any differences from Caucasian population?

P2860

Q55312983-D3C49EF2-834A-414E-A43A-CE4A1D906828

P2860

Nivolumab versus everolimus in advanced renal cell carcinoma: Japanese subgroup analysis from the CheckMate 025 study.

Item

http://www.wikidata.org/entity/Q47564905

description

2017 nî lūn-bûn

@nan

2017年の論文

@ja

2017年学术文章

@wuu

2017年学术文章

@zh

2017年学术文章

@zh-cn

2017年学术文章

@zh-hans

2017年学术文章

@zh-my

2017年学术文章

@zh-sg

2017年學術文章

@yue

2017年學術文章

@zh-hant

name

Nivolumab versus everolimus in ...... from the CheckMate 025 study.

@en

Nivolumab versus everolimus in ...... from the CheckMate 025 study.

@nl

type

Item

label

Nivolumab versus everolimus in ...... from the CheckMate 025 study.

@en

Nivolumab versus everolimus in ...... from the CheckMate 025 study.

@nl

prefLabel

Nivolumab versus everolimus in ...... from the CheckMate 025 study.

@en

Nivolumab versus everolimus in ...... from the CheckMate 025 study.

@nl

P1476

Nivolumab versus everolimus in ...... from the CheckMate 025 study.

@en

P2093

Elmer Berghorn

http://www.w3.org/2001/XMLSchema#string

Hiroshi Kitamura

http://www.w3.org/2001/XMLSchema#string

Hirotsugu Uemura

http://www.w3.org/2001/XMLSchema#string

Junji Yonese

http://www.w3.org/2001/XMLSchema#string

Kazunari Tanabe

http://www.w3.org/2001/XMLSchema#string

M Brent McHenry

http://www.w3.org/2001/XMLSchema#string

Masahiro Yao

http://www.w3.org/2001/XMLSchema#string

Masatoshi Eto

http://www.w3.org/2001/XMLSchema#string

Mototsugu Oya

http://www.w3.org/2001/XMLSchema#string

Nobuo Shinohara

http://www.w3.org/2001/XMLSchema#string

P2860

New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)

Adverse event profile and dose modification of everolimus for advanced renal cell carcinoma in real-world Japanese clinical practice.

Quality of life in patients with advanced renal cell carcinoma given nivolumab versus everolimus in CheckMate 025: a randomised, open-label, phase 3 trial.

Phase III trial of everolimus in metastatic renal cell carcinoma: subgroup analysis of Japanese patients from RECORD-1.

Angiogenesis inhibitor therapies for advanced renal cell carcinoma: toxicity and treatment patterns in clinical practice from a global medical chart review

Efficacy and safety of axitinib versus sorafenib in metastatic renal cell carcinoma: subgroup analysis of Japanese patients from the global randomized Phase 3 AXIS trial.

Key predictive factors for efficacy of axitinib in first-line metastatic renal cell carcinoma: subgroup analysis in Japanese patients from a randomized, double-blind phase II study.

A phase II study of sunitinib in Japanese patients with metastatic renal cell carcinoma: insights into the treatment, efficacy and safety.

Sorafenib-associated hand-foot syndrome in Japanese patients.

Key predictive factors of axitinib (AG-013736)-induced proteinuria and efficacy: a phase II study in Japanese patients with cytokine-refractory metastatic renal cell Carcinoma.

P304

639-646

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1093/JJCO/HYX049

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P50

Go Kimura

P577

2017-07-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

28419248

http://www.w3.org/2001/XMLSchema#string

P932

5896687

http://www.w3.org/2001/XMLSchema#string

Nivolumab versus everolimus in advanced renal cell carcinoma: Japanese subgroup analysis from the CheckMate 025 study.

about

P2860

P2860

Nivolumab versus everolimus in advanced renal cell carcinoma: Japanese subgroup analysis from the CheckMate 025 study.

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P304

P31

P356

P433

P478

P50

P577

P698

P932

P356

P1433

P1476

P2093

P2860

P304

P31

P356

P433

P478

P50

P577

P698

P932